Evidence map›Paper›PMID 30051333›Full record

ArticleCancer immunology, immunotherapy : CII2018

Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma.

Raj K Kurupati, Xiangyang Zhou, Zhiquan Xiang, Lorraine H Keller, Hildegund C J Ertl

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Raj K KurupatiThe Wistar Institute, 3601 Spruce Street, Philadelphia, PA, 19104, USA.
Xiangyang ZhouThe Wistar Institute, 3601 Spruce Street, Philadelphia, PA, 19104, USA.
Zhiquan XiangThe Wistar Institute, 3601 Spruce Street, Philadelphia, PA, 19104, USA.
Lorraine H KellerMBF Therapeutics, Inc., 640 Woodbrook Drive, Ambler, PA, 19002, USA.
Hildegund C J ErtlThe Wistar Institute, 3601 Spruce Street, Philadelphia, PA, 19104, USA. ertl@wistar.org.ORCID http://orcid.org/0000-0001-9795-5206
The Wistar Institute · USIo Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human immunotherapy with checkpoint blockades has achieved significant breakthroughs in recent years. In this study, a checkpoint blockade vaccine for canine melanoma was tested for safety and immunogenicity. Five healthy adult dogs received a mixture of three replication-defective chimpanzee-derived adenoviral vectors, one expressing mouse fibroblast-associated protein (mFAP) and the others expressing canine melanoma-associated antigens Trp-1 or Trp-2 fused into Herpes Simplex-1 glycoprotein D, a checkpoint inhibitor of herpes virus entry mediator (HVEM) pathways. The vaccine mixture was shown to be well tolerated and increased frequencies of canineTrp-1-specific activated CD8

Indexed as

ImmunotherapyAnimalsCancer VaccinesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDogsEndopeptidasesFibroblast Activation Protein AlphaGelatinasesGenetic VectorsInterferon-gammaInterleukin-2MaleMelanomaMembrane ProteinsMiceCancer VaccinesEndopeptidasesFibroblast Activation Protein AlphaGelatinasesInterferon-gammaInterleukin-2Membrane ProteinsOxidoreductasesSerine Endopeptidasestyrosinase-related protein-1Active immunotherapyCancerCancer-associated fibroblastsCheckpoint blockadeDogT-cell responses

Identifiers

PMID30051333
PMCPMC7080056
OpenAlexW2883032841

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.